Jens Panse News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Blueprint Medicines announces approval of AYVAKYT for treatment of ISM patients in Europe

Blueprint Medicines Corporation today announced the European Commission has approved AYVAKYT® (avapritinib) for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment. AYVAKYT is the first and only approved therapy for people living with ISM in Europe.

Associazione italiana mastocitosiPatrizia marcisGeorg pirmin meyerEuropean unionInternational at blueprint medicinesCommittee for medicinal products human useEuropean commissionBlueprint medicines corporationMedicines corporationPirmin meyerSenior vice presidentJens panseDeputy directorUniversity hospitalMedicinal productsHuman use

EC approves Blueprint s Ayvakyt as first treatment for rare haematological disorder

EC approves Blueprint s Ayvakyt as first treatment for rare haematological disorder
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Georg pirmin meyerEuropean commissionUniversity hospitalEuropean medicines agencyBlueprint medicine ayvakytJens pansePirmin meyerBlueprint medicines

EC approves treatment for rare haematological disorder

EC approves treatment for rare haematological disorder
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Georg pirmin meyerInternational at blueprint medicinesCommittee for medicinal products human useEuropean commissionBlueprint medicine ayvakytJens panseDeputy directorUniversity hospitalMedicinal productsHuman useSenior vice president

Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress

Omeros Corporation today announced that the slides presented yesterday in the “late-breaker” session at the 2023 European Hematology Association Congress in Frankfurt, Germany are now. | June 12, 2023

United kingdomMorag griffinEuropean hematology associationDepartment of hematologyJames university teaching hospitalOmeros corporation nasdaqUniversity hospitalScientific program committeeOmeros corporationHematology associationProgram committeeNormalizes hemoglobin levelsInterim dataProof of concept clinical trialJens panseSenior physician

EHA 2023 Late-Breaking Abstracts Offer Sneak Peek at the Future of Hematology

The late-breaking oral session at the European Hematology Association (EHA) 2023 Congress featured newly emerged data from abstracts submitted after the deadline, including outcomes from trials in polycythemia vera, acute myeloid leukemia, and more.

United statesSoult ukpyolsiSouth koreaUnited kingdomRepublic of koreaOksana karnabedaMarkj levisMarina kremyanskayaAmir fathiBrian huntlyUniversity hospital ulmEuropean hematology associationIcahn school of medicine at mount sinaiUniversity of aachenUniversity of cambridgeSamsung medical center